BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lv GC, Ma WJ, Ying LJ, Jin X, Zheng L, Yang YD. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. World J Gastroenterol 2010; 16(32): 4095-4099 [PMID: 20731026 DOI: 10.3748/wjg.v16.i32.4095]
URL: https://www.wjgnet.com/1007-9327/full/v16/i32/4095.htm
Number Citing Articles
1
Simone Regina Souza da Silva Conde, Luciana L. Rocha, Vanessa M. Ferreira, Julius Caesar Mendes Soares Monteiro, Nathália Karla Fonseca Filgueiras, Pedro Alves de Almeida Lins, Bruna Tereza Silva dos Santos, Felipe Bonfim Freitas, Ednelza da Silva Graça, Sâmia Demachki, Marialva Tereza Ferreira de Araújo, Ricardo Ishak, Antonio C. R. Vallinoto. Absence of Correlation between IL-28B Gene Polymorphisms and the Clinical Presentation of Chronic Hepatitis B in an Amazon Brazilian PopulationDisease Markers 2014; 2014: 1 doi: 10.1155/2014/534534
2
Jian Liang, Man Jun Jiang, Xin Deng, Xiao Xiao Zhou. Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis StudyHepatitis Monthly 2013; 13(5) doi: 10.5812/hepatmon.7862
3
Xiao-Feng Zhu, Li-Xia Lu, Ying Wang, Kong-wen Xu, Da-jiang Li, Xia Zhu, Li Liu, Cong Liu, Jin-Rong Wang, Hong Tang, Li-Chun Wang. Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis BHepatitis Monthly 2011; 11(12): 980 doi: 10.5812/kowsar.1735143X.4203
4
Meixin Hu, Guichan Liao, Sufang Wei, Zhe Qian, Hongjie Chen, Muye Xia, Qiuli Xie, Jie Peng. Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT < 2 Upper Limits of Normal: A Multi-center Retrospective Cohort StudyInfectious Diseases and Therapy 2023; 12(2): 637 doi: 10.1007/s40121-022-00757-y
5
Jiezuan Yang, Dong Yan, Renyong Guo, Jiajia Chen, Yongtao Li, Jun Fan, Xuyan Fu, Xinsheng Yao, Hongyan Diao, Lanjuan Li. Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatmentMedicine 2017; 96(10): e6242 doi: 10.1097/MD.0000000000006242
6
Hsien-Chung Yu, Kung-Hung Lin, Ping-I Hsu, Feng-Woei Tsay, Huay-Min Wang, Tzung-Jiun Tsai, Kwok-Hung Lai. Real-World Application of the Roadmap Model in Chronic Hepatitis B Patients with Telbivudine TherapyClinical Therapeutics 2013; 35(9): 1386 doi: 10.1016/j.clinthera.2013.07.329
7
Chia-Chi Wang, Chih-Lin Lin, Tsai-Yuan Hsieh, Kuo-Chih Tseng, Cheng-Yuan Peng, Tung-Hung Su, Sheng-Shun Yang, Yu-Chun Hsu, Tsung-Ming Chen, Jia-Horng Kao. Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in TaiwanHepatology International 2016; 10(2): 294 doi: 10.1007/s12072-015-9662-9
8
Weiyan Yu, Caiyan Zhao, Chuan Shen, Yadong Wang, Hongzhi Lu, Jing Fan, James Fung. The Efficacy and Safety of Nucleos(t)ide Analogues in Patients with Spontaneous Acute Exacerbation of Chronic Hepatitis B: A Systematic Review and Meta-AnalysisPLoS ONE 2013; 8(6): e65952 doi: 10.1371/journal.pone.0065952
9
Juan Wang, Ling-yao Du, Xia Zhu, En-qiang Chen, Hong Tang. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeksIndian Journal of Medical Microbiology 2015; 33: S20 doi: 10.4103/0255-0857.148827
10
Jiezuan Yang, Jiajia Chen, Ping Ye, Linfeng Jin, Wei Wu, Guoping Sheng, Lan-Juan Li. HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patientsJournal of Translational Medicine 2014; 12(1) doi: 10.1186/1479-5876-12-183
11
TelbivudineReactions Weekly 2021; 1853(1): 440 doi: 10.1007/s40278-021-95306-4